tetano
Editor, Senior Moderator
Nat Commun
. 2024 Oct 17;15(1):8941.
doi: 10.1038/s41467-024-53356-5. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19
August F Jernbom[SUP] 1 [/SUP], Lovisa Skoglund[SUP] 2 [/SUP], Elisa Pin[SUP] 2 [/SUP], Ronald Sjöberg[SUP] 2 [/SUP], Hanna Tegel[SUP] 3 [/SUP], Sophia Hober[SUP] 3 [/SUP], Elham Rostami[SUP] 4 5 [/SUP], Annica Rasmusson[SUP] 6 [/SUP], Janet L Cunningham[SUP] 6 [/SUP], Sebastian Havervall[SUP] 7 [/SUP], Charlotte Thålin[SUP] 7 [/SUP], Anna Månberg[SUP] 2 [/SUP], Peter Nilsson[SUP] 2 [/SUP]
Affiliations
Autoantibodies have been shown to be implied in COVID-19 but the emerging autoantibody repertoire remains largely unexplored. We investigated the new-onset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients at five time points over a 16-month period in 2020 and 2021 using proteome-wide and targeted protein and peptide arrays. Our results show that prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months. We found an increased prevalence of new-onset autoantibodies after severe COVID-19 and demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19. Using epitope mapping, we determined the main epitopes of selected new-onset autoantibodies, validated them in independent cohorts of neuro-COVID and pre-pandemic healthy controls, and identified sequence similarities suggestive of molecular mimicry between main epitopes and the conserved fusion peptide of the SARS-CoV-2 Spike glycoprotein. Our work describes the complexity and dynamics of the autoantibody repertoire emerging with COVID-19 and supports the need for continued analysis of the new-onset autoantibody repertoire to elucidate the mechanisms of the post-COVID-19 condition.
. 2024 Oct 17;15(1):8941.
doi: 10.1038/s41467-024-53356-5. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19
August F Jernbom[SUP] 1 [/SUP], Lovisa Skoglund[SUP] 2 [/SUP], Elisa Pin[SUP] 2 [/SUP], Ronald Sjöberg[SUP] 2 [/SUP], Hanna Tegel[SUP] 3 [/SUP], Sophia Hober[SUP] 3 [/SUP], Elham Rostami[SUP] 4 5 [/SUP], Annica Rasmusson[SUP] 6 [/SUP], Janet L Cunningham[SUP] 6 [/SUP], Sebastian Havervall[SUP] 7 [/SUP], Charlotte Thålin[SUP] 7 [/SUP], Anna Månberg[SUP] 2 [/SUP], Peter Nilsson[SUP] 2 [/SUP]
Affiliations
- PMID: 39414823
- DOI: 10.1038/s41467-024-53356-5
Autoantibodies have been shown to be implied in COVID-19 but the emerging autoantibody repertoire remains largely unexplored. We investigated the new-onset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients at five time points over a 16-month period in 2020 and 2021 using proteome-wide and targeted protein and peptide arrays. Our results show that prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months. We found an increased prevalence of new-onset autoantibodies after severe COVID-19 and demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19. Using epitope mapping, we determined the main epitopes of selected new-onset autoantibodies, validated them in independent cohorts of neuro-COVID and pre-pandemic healthy controls, and identified sequence similarities suggestive of molecular mimicry between main epitopes and the conserved fusion peptide of the SARS-CoV-2 Spike glycoprotein. Our work describes the complexity and dynamics of the autoantibody repertoire emerging with COVID-19 and supports the need for continued analysis of the new-onset autoantibody repertoire to elucidate the mechanisms of the post-COVID-19 condition.